Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study

share this :
• Management of breast cancer patients was modified during the pandemic. • Waiting time increased during the pandemic in 20% of the institutions. • A workload reduction of ≥50% was reported in 1/3 and relocation of the centres in 13%. • It is unknown whether these changes will affect outcome of breast cancer patients.
Below please find

Abstract

Currently, it is unclear which kind of axillary staging surgery breast cancer patients with lymph node metastasis should receive after neoadjuvant chemotherapy. For decades, these patients have been treated with a full axillary lymph node dissection, even if they converted to clinical node negativity. However, the removal of a large number of lymph nodes during the procedure can increase arm morbidity and impact quality of life. Therefore, several studies investigated less radical surgical strategies in this setting, such as sentinel lymph node biopsy or targeted axillary dissection, i.e., removal of a previously marked node combined with sentinel node removal. In this review, we summarize current evidence on the different surgical techniques and compare national and international recommendations. We show that many questions regarding oncological safety of different surgery types and the optimal marking technique remain unanswered and present the multinational prospective cohort study AXSANA that will address these open issues.

Full Publication

Become a member to stay updated!
The Benefits of EUBREAST Membership
Enter into a network of renowned international breast surgeons
Access to detailed information on ongoing and previous projects and events
Take part in international cross-border studies
Publish your EUBREAST membership status on your website / social media platforms together with the respective logo.